Geriatrics

(063) Association between Polypharmacy and the Risk of Chronic Kidney Disease in the Elderly Patients

(064) Battle of the Bisphosphonates: Global Utilization Trends for Osteoporosis between 2011 and 2022

(065) Bisphosphonates versus Denosumab: Assessing the Risk of Heart Failure in a Nationwide Retrospective Cohort Study in Taiwan

(066) Changes in long-term glucocorticoid use among older adults after new diagnosis of late-onset rheumatoid arthritis

(067) Clinical outcomes of discontinuing long-term opioid therapy among older cancer survivors in nursing homes

(068) Contemporary Management of Patients After Hip Fracture. A Population-Based Cohort of Over 120.000 Patients in Spain.

(070) Disability Phenotypes among Medicare Beneficiaries with Dementia: Implications for Longitudinal Confounding Control, Risk Stratification, and Comparative Effectiveness Research

(072) Drug Holiday of Oral Bisphosphonates and Mortality following Hip Fracture: A Population-based Cohort Study

(076) Incidence of opioid dose tapering among older adults enrolled in Medicare

(077) Large scale propensity score matching with time-stratification in older women with or without fractures in the UK

(079) Medication Use Patterns Among Older Adults With Obstructive Sleep Apnea With and Without Comorbid Insomnia

(080) Opioid Deprescribing Rates in Older Adults with Frailty and Risk Factors for Prolonged Use after an Acute Fracture

(081) Patterns of Concurrent Opioid and Benzodiazepine Use Discontinuation among Medicare Beneficiaries 2016-2018

(083) A Case-control Study On Polypharmacy And Co-medications in Alzheimer’s Disease

(083) Trajectories of Analgesic Agent Use and Adverse Clinical Outcomes Among Older Adults: a Nationwide Cohort Study

(084) A dynamic fall risk prediction and monitoring tool in aged care using routinely collected electronic health data: Development and internal validation of the FRIPAC tool

(084) Trends in Central Nervous System Medication Use among Assisted Living Residents with Cognitive Impairment: Variation by Presence of Dementia Care and the COVID-19 Pandemic

(086) Adverse Drug reactions in an Ageing PopulaTion rIsk Prediction Tool (ADAPtIP): the development of a model for predicting adverse drug reactions in older patients admitted to hospital

(087) Anticoagulant Deprescribing After An Emergency Department Visit Due To Gastrointestinal Bleeding Among Older Patients Using Multiple Medications

(089) Are drugs discontinued after hospital-based medication reviews in older adults? A nationwide register-based study in 2022

(091) Association between use of Furosemide and Risk of Parkinson’s disease

(093) Associations between gender, race/ethnicity and age and the initiation of chronic high-risk medication in US older adults

(094) Brain Imaging In United States Veterans Before and After Establishing Criteria for Use of Anti-amyloid Therapy for Treatment of Mild Cognitive Impairment and Alzheimer’s Dementia

(095) Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

(096) Comparing Dementia and Cognitive Impairment Risks in Older Type-2 Diabetic Patients: A Danish Register-Based Study on Dipeptidyl Peptidase-4 Inhibitors vs. Glucagon-like Peptide-1 Analogues

(097) Cost-Effectiveness of Lecanemab (Leqembi) for Individuals With Early-Stage Alzheimer’s Disease

(098) Dementia Medications and their Association with Pain Medication Use in Medicare Beneficiaries with Dementia and Chronic Pain

(099) Description of time trends in the of users of Janus kinase inhibitors in Sweden using a joinpoint regression approach

(100) Developing a novel claim-based algorithm to identify incident and prevalent dementia using Medicare claims of the Atherosclerosis Risk in Communities (ARIC) cohort

(101) Discontinuation of chronically used medication in routine clinical practice among Swedish older adults: A nationwide cohort study

(102) Drug target Mendelian Randomisation vs regression methods: estimating causal effects of sclerostin inhibition on bone mineral density and fracture risk

(103) Effectiveness and Safety of Oral Anticoagulants among Long-term Nursing Home Residents with atrial fibrillation (AF) and Moderate to Severe Impairment in Functional Status

(104) Effectiveness of Gabapentinoids versus Muscle Relaxants on Opioid Discontinuation among Older Adults with Prolonged Opioid Use

(106) Epidemiological Landscape of Human Metapneumovirus Among Older Adults in High-Income Countries: Systematic Literature Review and Meta-Analysis

(107) Estimating the Prevalence of Preclinical Alzheimer’s Disease with Subjective Cognitive Decline among US Adults

(108) Evaluating Caregiver Quality of Life, Indirect and Intangible Costs and their Association with Alzheimer’s Disease Severity in the US

(110) Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities with Alzheimer's Disease or Mild Cognitive Impairment

(111) Evaluation of QT Prolonging Drug Use Among Elderly with Psychiatric Disorders in India using Beers Criteria(2019) and STOPP Criteria(2015)

(114) Exploring the Feasibility and added Value of a Comorbidity Index Score in a Pharmacovigilance Database

(115) Factors associated with potentially inappropriate medicines use in older adults during the covid-19 pandemic in two Brazilian municipalities: a cross-sectional study

(116) Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture

(117) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study

(118) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-harm in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study

(119) Glucose lowering medication utilization before and after entry into long-term care among older people with diabetes

(120) How much frequently are biological drugs used in patients over 65 years with immune-mediated inflammatory diseases through the Italian VALORE distributed database network

(121) Identifying Clustering of Clinic-level Prescribing Patterns for Patients with Differing Health Coverage in Primary Care in Ireland: a Cohort Study

(123) Improving Prescription Appropriateness of Proton Pump Inhibitors: The LAPTOP-PPI Study

(124) Incidence and Complications of Rectopexy in the United Kingdom and United States, 2013-2022.

(126) Medicare Annual Wellness Visits and Incident Alzheimer’s Disease Diagnosis among a Medicare Advantage Population, 2016-2022

(127) National trends in utilization of glucose lowering medications by older people with diabetes in long-term care facilities, 2009 to 2019

(128) Network Analysis of Chronic Medication Use in Older Adults Living with Dementia Prior to and Following Diagnosis: A Web-based Visualisation Tool

(129) Older US adults refilling potentially inappropriate medications after hip fracture

(130) PARTNER pilot study: Interprofessional clinical pathway to patient-oriented deprescribing of psychotropic and anticholinergic medications in elderly patients with polypharmacy

(131) Pharmacological treatments and medication-related problems in nursing homes in Catalonia: The impact of a multidisciplinary team intervention

(132) Polypharmacy and Potentially Inadequate Medication in Older Adults: Results from the German National Cohort (NAKO) Baseline.

(133) Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom

(135) Primary Care Resource Utilisation and Costs of Fragility Fractures in Postmenopausal Women in the UK Using CPRD Data Mapped to OMOP Common Data Model

(136) Regional Variations Between Drug Treatment Recommendations for Insomnia in Older People in Sweden

(137) Risk of sarcopenia following long-term statin use in community-dwelling middle-aged and older adults in Japan: evidence from a 10-year population-based cohort study using propensity score matching and overlap weighting

(138) Risk of ventricular arrhythmias or sudden cardiac death and acetylcholinesterase inhibitors among older adults with dementia

(139) Risk Prediction Models for Adverse Drug Reactions and Adverse Drug Events in Older Adults – A Systematic Review

(141) Spousal bereavement and four-year trajectories of medication use: a nationwide register-based study in Swedish older adults

(142) Telehealth's Impact in Alzheimer's Medication Management: A Real-World EMR Analysis

(143) The prevalent new-user study design: a novel application to estimating the average treatment effect of statin discontinuation on mortality among traditional Medicare beneficiaries who discontinued statins

(144) Trends of the prevalence of polypharmacy and potentially inappropriate medications in people with dementia from 2006 to 2021 in Hong Kong

(145) Unraveling the use of diagnostic tests for mild cognitive impairment, Alzheimer’s disease, and other dementias: a real-world study

(146) Use of Immunomodulators/Biologics is protective against Major Adverse Cardiovascular Events in Medicare patients with Inflammatory Bowel Disease over use of 5-ASA alone.

(147) Which Medication Counting Method is Useful for Predicting Death and Institutionalization in Older Adults? A Population-Based Cohort Study